The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global next generation sequencing (NGS) market reached a value of US$ 11.66 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 19.5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Next-generation sequencing, or high-throughput sequencing, refers to the process of determining the sequence of nucleotides in a section of the DNA. It includes procedures such as sequencing by synthesis (SBS), ion semiconductor sequencing, nanopore sequencing and single-molecule real-time (SMRT) sequencing. It is a cost-effective solution that offers precise results with high accuracy and speed. This enables the analysis of millions of DNA molecules simultaneously, which facilitates research in the fields of personalized and genetic medicines, agriculture and animal research, and clinical diagnostics.
Next Generation Sequencing (NGS) Market Drivers:
The increasing prevalence of chronic medical ailments, such as cancer, along with various technological advancements in the field of medical sciences, is one of the key factors driving the growth of the market. Owing to the widespread adoption of liquid biopsies in cancer diagnostics, there has been a significant increase in the utilization of NGS technologies. These technologies utilize cell-free circulating tumor DNA (ctDNA) as a non-invasive cancer biomarker for real-time cancer monitoring and detection. Furthermore, the increasing adoption of genome mapping programs to predict the development of various diseases is also providing a boost to the market growth. Genetic maps are used for guiding scientists to analyze the genes that are responsible for increasing the prevalence of diabetes, heart diseases, asthma, cancer and psychiatric conditions. Additionally, various technological advancements and integration with the cloud-computing systems for improved data management, are creating a positive impact on the market growth. Other factors, including the declining costs of NGS systems and extensive research and development (R&D) activities in the field of sequencing chemistry, molecular biology and technical engineering, are projected to drive the global next generation sequencing market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global next generation sequencing, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on sequencing type, product type, technology, application and end user.
Breakup by Sequencing Type:
Breakup by Product Type:
Breakup by Technology:
Breakup by Application:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies, Becton Dickinson and Company, 10x Genomics, BGI Group, Eurofins Scientific, F. Hoffmann-La Roche AG, Illumina Inc., Genewiz, Macrogen, Oxford Nanopore Technologies, Pacific Biosciences, PerkinElmer, Thermo Fisher Scientific, Qiagen N.V., GenapSys Inc., etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Sequencing Type, Product Type, Technology, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Agilent Technologies, Becton Dickinson and Company, 10x Genomics, BGI Group, Eurofins Scientific, F. Hoffmann-La Roche AG, Illumina Inc., Genewiz, Macrogen, Oxford Nanopore Technologies, Pacific Biosciences, PerkinElmer, Thermo Fisher Scientific, Qiagen N.V. and GenapSys Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
We expect the global next-generation sequencing (NGS) market to exhibit a CAGR of 19.5% during 2021-2026.
Sudden outbreak of the COVID-19 pandemic has led to an increasing demand for next generation sequencing process as it assists in identifying the mutations and transmission routes in the body that is causing the spread of the virus.
The increasing prevalence of cancer, along with various technological advancements in the field of medical sciences represent some of the factors catalyzing the global next-generation sequencing (NGS) market.
Based on the sequencing type, the global next-generation sequencing (NGS) market can be segmented into whole genome sequencing, targeted resequencing, whole exome sequencing, RNA sequencing, CHIP sequencing, De Novo Sequencing, Methyl sequencing, and others, where targeted resequencing holds the majority of the market share.
Based on the product type, the global next-generation sequencing (NGS) market has been segregated into instruments, reagents and consumables, and software and services. Among these, reagents and consumables currently represent the largest segment.
Based on the technology, the global next-generation sequencing (NGS) market can be categorized into sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, nanopore sequencing, and others. Currently, sequencing by synthesis exhibits a clear dominance in the market.
Based on the end-user, the global next-generation sequencing (NGS) market has been divided into academic institutes & research centers, hospitals & clinics, pharmaceutical & biotechnology companies, and others. Amongst these, academic institutes & research centers currently account for the majority of the total market share.
Based on the application, the global next-generation sequencing (NGS) market can be bifurcated into biomarker and cancer, drug discovery and personalized medicine, genetic screening, diagnostics, agriculture and animal research and others. Currently, biomarker and cancer represent the largest segment.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global next-generation sequencing (NGS) market include Agilent Technologies, Becton Dickinson and Company, 10x Genomics, BGI Group, Eurofins Scientific, F. Hoffmann-La Roche AG, Illumina Inc., Genewiz, Macrogen, Oxford Nanopore Technologies, Pacific Biosciences, PerkinElmer, Thermo Fisher Scientific, Qiagen N.V., GenapSys Inc., etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at